



## Appendix B: Medications Used in Palliative Care for Nausea and Vomiting

Tailor dose to each patient; those who are elderly, cachectic, debilitated or with renal or hepatic dysfunction may require reduced dosages; consult most current product monograph for this information: <http://www.bc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php>

ANTI-EMETICS <sup>A</sup>						
Generic Name	Trade Name	Available Dosage Forms	Standard Adult Dose	Drug Plan Coverage <sup>B</sup>		Approx. cost per 30 days <sup>C</sup>
				Palliative Care	Fair PharmaCare	
<b>dimenhydrinate</b>	Gravol <sup>®</sup> , G	<b>IR caps/tabs:</b> 15, 50 mg	50 mg PO q6h to q4h	Yes, LCA	No	\$3–4 (G)
		<b>L/A caplets:</b> 100 mg	100 mg PO q12h to q8h	Yes	No	\$22–33
		<b>Inj:</b> 50 mg per mL	50 mg IM/IV/SC <sup>D</sup> q6h to q4h	Yes, LCA	No	\$140–210 (G) \$157–235
		<b>Supps:</b> 25, 50, 100 mg	50 to 100 mg PR q12h to q8h	Yes	No	\$35–53 (G) \$38–100
<b>domperidone</b>	G	<b>Tab:</b> 10 mg	10 to 20 mg PO tid to qid	Yes, LCA	Yes, LCA	\$6–16 (G)
<b>methotrimeprazine</b>	G	<b>Tabs:</b> 2, 5, 25, 50 mg	5 to 12.5 mg PO q4h to q24h	Yes, LCA	Yes, LCA	\$3–25 (G)
	Nozinan <sup>®</sup>	<b>Inj:</b> 25 mg per mL	6.25 to 25 mg SC <sup>D</sup> q4h to q24h	Yes	Yes	\$112–673
<b>metoclopramide</b>	G	<b>Tab:</b> 5, 10 mg	5 to 20 mg PO qid	Yes, LCA	Yes, LCA	\$8–16 (G)
		<b>Inj:</b> 5 mg per mL	10 to 20 mg SC <sup>D</sup> /IV q6h	Yes, LCA	Yes, LCA	\$13–1759 (G)
<b>haloperidol<sup>E</sup></b>	G	<b>Tabs:</b> 0.5, 1, 2, 5, 10 mg	0.5 mg PO/SC <sup>D</sup> /IV bid to 2.5 mg q6h	Yes, LCA	Yes, LCA	\$8–31 (G)
		<b>Inj:</b> 5 mg per mL		Yes, LCA	Yes, LCA	\$312–625 (G)
<b>prochlorperazine</b>	G	<b>Tabs:</b> 5, 10 mg	5 to 10 mg PO/PR tid-qid	Yes, LCA	Yes, LCA	\$16–27 (G)
		<b>Supp:</b> 10 mg				\$154–207 (G)
<b>dexamethasone</b>	G	<b>Tabs:</b> 0.5, 0.75, 2, 4 mg	2 mg PO/SC <sup>D</sup> /IV daily to 8 mg bid (AM & noon)	Yes, LCA	Yes, LCA	\$16–124 (G)
		<b>Inj:</b> 4, 10 mg per mL				\$6–22 (G)
<b>nabilone</b>	Cesamet <sup>®</sup> , G	<b>Caps:</b> 0.25, 0.5, 1 mg	1 to 2 mg PO bid	No	Yes, LCA	\$100–201 (G) \$430–861
<b>scopolamine<sup>E</sup></b>	Transderm V <sup>®</sup>	<b>Patch:</b> 1.5 mg	1 to 2 <sup>F</sup> patches applied to skin every 72 hours	Yes	Yes	\$44–88
<b>olanzapine</b>	Zyprexa <sup>®</sup> , G	<b>Tab:</b> 2.5, 5, 7.5, 10, 15, 20 mg	5 to 10 mg PO q8h prn	No	Special Authority, LCA	\$62–124 (G) \$118–235
	Zyprexa Zydis <sup>®</sup> , G	<b>ODT:</b> 5, 10, 15, 20 mg				\$63–125 (G) \$117–234

## ANTI-EMETICS<sup>A</sup>

Generic Name	Trade Name	Available Dosage Forms	Standard Adult Dose	Drug Plan Coverage <sup>B</sup>		Approx. cost per 30 days <sup>C</sup>
				Palliative Care	Fair PharmaCare	
<b>octreotide<sup>E</sup></b>	Sandostatin <sup>®</sup> , G	<b>Inj:</b> 50, 100, 200, 500 mcg per mL	50 to 200 mcg SC q8h	Yes, LCA	No	\$170–616 (G) \$485–1761
	Sandostatin LAR <sup>®</sup>	<b>Inj LAR:</b> 10, 20, 30 mg per vial	10 to 30 mg IM every 4 weeks	No	No	\$1427–2365
<b>ondansetron</b>	Zofran <sup>®</sup> , G	<b>IR tabs:</b> 4, 8 mg	4 to 8 mg PO/SC q8h to q12h	No	Special Authority, LCA	\$212–485 (G) \$868–1987
		<b>ODT:</b> 4, 8 mg				\$212–485 (G) \$848–1941
		<b>Inj:</b> 2mg per mL				\$448–1343 (G) \$692–2077
<b>granisetron</b>	G	<b>Tab:</b> 1 mg	1 mg to 2 mg PO/IV/SC <sup>D</sup> daily or 1 mg bid	No	Special Authority, LCA	\$554–1108 (G)
		<b>Inj:</b> 1 mg per mL				No
<b>cannabidiol, D-9-T</b>	Sativex <sup>®</sup>	<b>Buccal spray:</b> single combination product strength	1 spray buccally/ sublingual BID, increase by 1 spray per day up to 8 to 12 sprays per day	No	No	\$588–882
<b>aprepitant</b>	Emend <sup>®</sup>	<b>Caps:</b> 80, 125 mg	125 mg PO to start, then 80 mg PO once daily	No	Special Authority	\$1050

**Abbreviations:** **caps** capsules; **D-9-T** Delta-9-Tetrahydrocannabinol; **G** generics; **Inj** injection; **IM** intramuscular; **IR** immediate release; **IV** intravenous; **LCA** subject to Low Cost Alternative Program; **L/A** Long acting (combined immediate and sustained release); **LAR** slow release (injection); **PR** per rectum; **ODT** orally disintegrating tablet; **PO** by mouth; **SC** subcutaneous; **supps** suppositories (rectal); **tabs** tablets

<sup>A</sup> Refer to guideline and/or algorithm for recommended order of use.

<sup>B</sup> PharmaCare coverage as of October 2016 (subject to revision). Obtain current coverage, eligibility, and coverage information from the online BC PharmaCare Formulary Search page at [pharmacareformularysearch.gov.bc.ca](http://pharmacareformularysearch.gov.bc.ca)

<sup>C</sup> Cost as of October 2016 and does not include retail markups or pharmacy fees. Generic and brand name cost separated as indicated by (G).

<sup>D</sup> This route of administration commonly used in Palliative Care, but not approved by Health Canada

<sup>E</sup> This indication (i.e. nausea and vomiting) used in practice, but not approved for marketing by Health Canada.

<sup>F</sup> Dose of 2 patches of scopolamine transdermal patch (applied simultaneously) used in practice, but not approved for marketing by Health Canada.